Eli Lilly has confirmed plans for a $1.3 billion takeover bid for Verve Therapeutics, upgrading a collaboration between the ...

Factor XIIa inhibitor Andembry (garadacimab) has been cleared in the US for use in patients aged 12 and over with HAE, which ...